Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years?
Key PointsAdoption by insurers and FDA approval are critical for future performance.
Grail's stock has experienced an impressive surge of 171% in just six months, demonstrating strong growth. However, the company's overall stock performance over the past year has been less impressive, with a 64% increase in 2026. This difference in stock performance can be attributed to Grail's recovery following a challenging period in mid-February, when the company announced it had not met the primary endpoint in a crucial trial.
To understand where Grail's stock may be in the next five years, it's important to examine the company's current financial situation and projected growth. As of now, Grail is not profitable nor cash-generative, and Wall Street analysts project this will not change until 2032 or 2033. This may make the stock appear less attractive to some investors.
Nevertheless, it's worth considering that if these estimates hold true, Grail's revenue could grow at a rate of 30% as its MCED test, Galleri, gains wider adoption by medical insurers. Test sales are expected to increase significantly from 247,000 in 2026 to a projected 832,000 in 2030.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
